Mechanistic insights into chloride-related heart failure progression according to the plasma volume status.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
06 2022
Historique:
revised: 04 03 2022
received: 20 12 2021
accepted: 28 03 2022
pubmed: 7 4 2022
medline: 6 5 2022
entrez: 6 4 2022
Statut: ppublish

Résumé

Two types of heart failure (HF) progression were recently proposed on the basis of an increased vs. non-increased serum chloride concentration. The applicability of this concept to real-world HF pathophysiology requires further investigation. The present study evaluated the mechanisms of HF progression to a different type according to changes in the estimated plasma volume status (ePVS). Data from 47 patients (32% men; 78.2 ± 9.7 years of age) with stable to worsening HF (37.5 ± 16 days) were analysed. Physical examination, standard blood tests, and b-type natriuretic peptide (BNP) measurements were conducted. The ePVS was calculated as follows: ePVS (dL/g) = [100 - haematocrit (%)]/[haemoglobin (g/dL)]. For the study subjects as a whole (n = 47), changes in the ePVS correlated positively with changes in the serum chloride concentration from stable to worsening HF (r = 0.398, P = 0.0056). When divided into two groups of worsening HF with an increased (n = 31) vs. non-increased serum chloride concentration (n = 16), no significant baseline differences in body weight, serum logBNP, or ePVS were detected between groups. Under worsening HF, the increase in body weight (2.34 ± 1.12 vs. 2.59 ± 1.56 kg, P = 0.57) and logBNP (0.39 ± 0.30 vs. 0.54 ± 0.31 pg/mL, P = 0.13) did not differ between groups, but the increase in the ePVS was smaller in the group with a non-increased serum chloride concentration compared with that with an increased serum chloride concentration (0.292 ± 0.49 vs. 0.653 ± 0.60 dL/g, P = 0.044). An increase in the %change in ePVS ≥ 10% was less common in patients with a non-increased chloride concentration (37% vs. 71%, P = 0.03). Patients with a non-increased serum chloride concentration had more HF signs (3.31 ± 0.79 vs. 2.65 ± 0.71, P = 0.005) and a higher incidence of pulmonary rales (63% vs. 16%, P = 0.0024) than those with an increased serum chloride concentration. According to the changes in the ePVS, HF progression may result from a difference between two HF types (i.e. increased vs. non-increased serum chloride concentration) in the cardiac reserve in response to a given cardiac burden by modulating plasma volume status via the possible tonicity potential of chloride.

Identifiants

pubmed: 35384366
doi: 10.1002/ehf2.13927
pmc: PMC9065841
doi:

Substances chimiques

Chlorides 0
Hemoglobins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2044-2048

Informations de copyright

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Cardiol Ther. 2020 Dec;9(2):227-244
pubmed: 32378135
Eur J Heart Fail. 2017 Feb;19(2):226-236
pubmed: 27758007
Cardiol Ther. 2021 Dec;10(2):407-428
pubmed: 34398440
J Am Coll Cardiol. 2013 Aug 6;62(6):516-24
pubmed: 23747773
Clin Res Cardiol. 2019 May;108(5):563-573
pubmed: 30370469
Med Hypotheses. 2017 Jul;104:170-173
pubmed: 28673579
Eur J Heart Fail. 2015 Jul;17(7):689-96
pubmed: 25924078
Int J Cardiol. 2017 Mar 1;230:556-561
pubmed: 28062134
Cardiol Ther. 2020 Dec;9(2):333-347
pubmed: 32772346
Eur J Heart Fail. 2014 Feb;16(2):133-42
pubmed: 24464967
J Card Fail. 2019 Apr;25(4):240-248
pubmed: 30528705
JACC Heart Fail. 2015 Nov;3(11):886-93
pubmed: 26541787
Eur J Heart Fail. 2018 Oct;20(10):1426-1435
pubmed: 29943886
ESC Heart Fail. 2015 Dec;2(4):106-115
pubmed: 28834618
J Card Fail. 2019 Mar;25(3):213-217
pubmed: 30296584
Circulation. 1954 May;9(5):706-18
pubmed: 13161102
ESC Heart Fail. 2022 Jun;9(3):2044-2048
pubmed: 35384366
J Am Soc Nephrol. 2007 Jul;18(7):2028-31
pubmed: 17568020
ESC Heart Fail. 2017 Nov;4(4):623-631
pubmed: 29154432

Auteurs

Hajime Kataoka (H)

Department of Internal Medicine, Nishida Hospital, Tsuruoka-Nishi-Machi 2-266, Saiki, Oita, 876-0047, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH